WO2006110761A3 - A variant form of urate oxidase and use thereof - Google Patents

A variant form of urate oxidase and use thereof Download PDF

Info

Publication number
WO2006110761A3
WO2006110761A3 PCT/US2006/013502 US2006013502W WO2006110761A3 WO 2006110761 A3 WO2006110761 A3 WO 2006110761A3 US 2006013502 W US2006013502 W US 2006013502W WO 2006110761 A3 WO2006110761 A3 WO 2006110761A3
Authority
WO
WIPO (PCT)
Prior art keywords
variant form
urate oxidase
proteins
relates
urate oxidases
Prior art date
Application number
PCT/US2006/013502
Other languages
French (fr)
Other versions
WO2006110761A2 (en
Inventor
Jacob Hartman
Simona Mendelovitz
Original Assignee
Savient Pharmaceuticals Inc
Jacob Hartman
Simona Mendelovitz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals Inc, Jacob Hartman, Simona Mendelovitz filed Critical Savient Pharmaceuticals Inc
Priority to NZ562291A priority Critical patent/NZ562291A/en
Priority to EP06740863A priority patent/EP1871877A2/en
Priority to MX2007012548A priority patent/MX2007012548A/en
Priority to BRPI0612942-0A priority patent/BRPI0612942A2/en
Priority to JP2008505656A priority patent/JP2008535499A/en
Priority to AU2006235437A priority patent/AU2006235437B2/en
Priority to US11/918,296 priority patent/US7811800B2/en
Priority to CN2006800206898A priority patent/CN101194016B/en
Priority to HU0700729A priority patent/HU229626B1/en
Priority to KR1020077026114A priority patent/KR101304289B1/en
Priority to CA002604545A priority patent/CA2604545A1/en
Priority to US11/539,475 priority patent/US8148123B2/en
Publication of WO2006110761A2 publication Critical patent/WO2006110761A2/en
Publication of WO2006110761A3 publication Critical patent/WO2006110761A3/en
Priority to US11/899,688 priority patent/US20080159976A1/en
Priority to IL186511A priority patent/IL186511A/en
Priority to US12/879,084 priority patent/US7964381B2/en
Priority to IL208643A priority patent/IL208643A0/en
Priority to US13/107,498 priority patent/US8034594B2/en
Priority to US13/226,891 priority patent/US8178334B2/en
Priority to US13/452,151 priority patent/US8293228B2/en
Priority to US13/623,512 priority patent/US8465735B2/en
Priority to IL223477A priority patent/IL223477A/en
Priority to IL223476A priority patent/IL223476A/en
Priority to IL256157A priority patent/IL256157B/en
Priority to IL281228A priority patent/IL281228A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase

Abstract

The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases.
PCT/US2006/013502 2005-04-11 2006-04-11 A variant form of urate oxidase and use thereof WO2006110761A2 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
NZ562291A NZ562291A (en) 2005-04-11 2006-04-11 A variant form of urate oxidase and use thereof
EP06740863A EP1871877A2 (en) 2005-04-11 2006-04-11 A variant form of urate oxidase and use thereof
MX2007012548A MX2007012548A (en) 2005-04-11 2006-04-11 A variant form of urate oxidase and use thereof.
BRPI0612942-0A BRPI0612942A2 (en) 2005-04-11 2006-04-11 variant form of urate oxidase and its use
JP2008505656A JP2008535499A (en) 2005-04-11 2006-04-11 Mutant urate oxidase and use thereof
AU2006235437A AU2006235437B2 (en) 2005-04-11 2006-04-11 A variant form of urate oxidase and use thereof
US11/918,296 US7811800B2 (en) 2005-04-11 2006-04-11 Variant form of urate oxidase and use thereof
CN2006800206898A CN101194016B (en) 2005-04-11 2006-04-11 A variant form of urate oxidase and use thereof
HU0700729A HU229626B1 (en) 2005-04-11 2006-04-11 A variant form of urate oxidase and use thereof
KR1020077026114A KR101304289B1 (en) 2005-04-11 2006-04-11 A variant form of urate oxidase and use thereof
CA002604545A CA2604545A1 (en) 2005-04-11 2006-04-11 A variant form of urate oxidase and use thereof
US11/539,475 US8148123B2 (en) 2005-04-11 2006-10-06 Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US11/899,688 US20080159976A1 (en) 2005-04-11 2007-09-07 Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
IL186511A IL186511A (en) 2005-04-11 2007-10-09 Variant form of urate oxidase and use thereof
US12/879,084 US7964381B2 (en) 2005-04-11 2010-09-10 Variant form of urate oxidase and use thereof
IL208643A IL208643A0 (en) 2005-04-11 2010-10-12 A variant form of urate oxidase and use thereof
US13/107,498 US8034594B2 (en) 2005-04-11 2011-05-13 Variant form of urate oxidase and use thereof
US13/226,891 US8178334B2 (en) 2005-04-11 2011-09-07 Variant form of urate oxidase and use thereof
US13/452,151 US8293228B2 (en) 2005-04-11 2012-04-20 Variant form of urate oxidase and use thereof
US13/623,512 US8465735B2 (en) 2005-04-11 2012-09-20 Variant form of urate oxidase and use thereof
IL223476A IL223476A (en) 2005-04-11 2012-12-06 Method of preparing isolated modified uricase
IL223477A IL223477A (en) 2005-04-11 2012-12-06 Pharmaceutical composition comprising modified uricase
IL256157A IL256157B (en) 2005-04-11 2017-12-06 Method of preparing isolated modified uricase
IL281228A IL281228A (en) 2005-04-11 2021-03-03 A variant form of urate oxidase and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67054105P 2005-04-11 2005-04-11
US60/670,541 2005-04-11

Related Child Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2006/013660 Continuation-In-Part WO2006110819A2 (en) 2005-04-11 2006-04-11 Variant forms of urate oxidase and use thereof
US11/918,296 A-371-Of-International US7811800B2 (en) 2005-04-11 2006-04-11 Variant form of urate oxidase and use thereof
US11/539,475 Continuation-In-Part US8148123B2 (en) 2005-04-11 2006-10-06 Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US12/879,084 Division US7964381B2 (en) 2005-04-11 2010-09-10 Variant form of urate oxidase and use thereof

Publications (2)

Publication Number Publication Date
WO2006110761A2 WO2006110761A2 (en) 2006-10-19
WO2006110761A3 true WO2006110761A3 (en) 2007-03-08

Family

ID=37087650

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/013502 WO2006110761A2 (en) 2005-04-11 2006-04-11 A variant form of urate oxidase and use thereof

Country Status (18)

Country Link
US (6) US7811800B2 (en)
EP (2) EP1871877A2 (en)
JP (3) JP2008535499A (en)
KR (1) KR101304289B1 (en)
CN (2) CN101194016B (en)
AU (1) AU2006235437B2 (en)
BR (1) BRPI0612942A2 (en)
CA (1) CA2604545A1 (en)
CZ (1) CZ2007700A3 (en)
HU (1) HU229626B1 (en)
IL (6) IL186511A (en)
MX (1) MX2007012548A (en)
NZ (1) NZ562291A (en)
PL (1) PL215157B1 (en)
RU (1) RU2435847C2 (en)
SG (3) SG2014009484A (en)
TW (1) TW200716751A (en)
WO (1) WO2006110761A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1588716E (en) * 1998-08-06 2011-05-25 Mountain View Pharmaceuticals Peg-urate oxidase conjugates and use thereof
JP2008535500A (en) 2005-04-11 2008-09-04 サビエント ファーマセウティカルズ インク． Mutant urate oxidase and use thereof
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
CN101622270B (en) * 2006-04-12 2014-01-01 萨文特医药公司 Method for purification of proteins with cationic surfactant
JP4890133B2 (en) * 2006-07-20 2012-03-07 東洋紡績株式会社 Stable uric acid measurement reagent
JP4890132B2 (en) * 2006-07-20 2012-03-07 東洋紡績株式会社 Method for improving specific activity of uricase and modified uricase with improved specific activity
JP4890134B2 (en) * 2006-07-20 2012-03-07 東洋紡績株式会社 Method for improving the stability of uricase, and modified uricase with improved stability
SG176897A1 (en) 2009-06-25 2012-01-30 Savient Pharmaceuticals Inc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
CN102051348B (en) 2009-10-27 2012-10-03 重庆富进生物医药有限公司 Humanized recombinant uricase and mutant thereof
WO2011127393A2 (en) 2010-04-08 2011-10-13 Georgia Tech Research Corporation Variants of ancestral uricases and uses thereof
CN102634492B (en) 2011-02-14 2015-06-10 重庆富进生物医药有限公司 Polyethylene glycol dog source urate oxidase analogue, and preparation method and applications thereof
CN102827073A (en) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 Therapeutically active compositions and application methods thereof
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2014170916A2 (en) 2013-04-17 2014-10-23 Council Of Scientific & Industrial Research Novel uricase mutants
JP6529492B2 (en) 2013-07-11 2019-06-12 アジオス ファーマシューティカルズ， インコーポレイテッド 2,4- or 4,6-Diaminopyrimidine Compounds as IDH2 Mutant Inhibitors for the Treatment of Cancer
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
AU2015229214B2 (en) 2014-03-14 2019-07-11 Les Laboratoires Servier Pharmaceutical compositions of therapeutically active compounds
AU2016265677B2 (en) * 2015-05-15 2021-12-09 Medimmune, Llc Improved uricase sequences and methods of treatment
CN106554948B (en) * 2015-09-29 2019-06-25 上海生物制品研究所有限责任公司 Saltant type uricase, the saltant type uricase of PEG modification and its application
BR112018007656A2 (en) 2015-10-15 2018-11-06 Agios Pharmaceuticals Inc combination therapy for treatment of malignant diseases
CA3216701A1 (en) 2015-10-15 2017-04-20 Les Laboratoires Servier Combination therapy for treating malignancies
CN116637177A (en) 2016-11-11 2023-08-25 好利恩治疗美国公司 Combination therapy of prednisone and uricase molecules and uses thereof
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CN109207479A (en) * 2018-09-07 2019-01-15 大连大学 Marine low temperature urate oxidase promoter and terminator
CN111088268B (en) * 2019-03-05 2022-08-02 北京锦篮基因科技有限公司 Gene therapy medicine for hyperuricemia
CN113244412B (en) * 2021-06-25 2021-10-26 深圳市瑞吉生物科技有限公司 Medicine for treating hyperuricemia or gout based on mRNA dosage form and preparation method thereof
WO2023233034A1 (en) 2022-06-03 2023-12-07 Boehringer Ingelheim International Gmbh Recombinant expression of myeloid-derived growth factor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000008196A2 (en) * 1998-08-06 2000-02-17 Duke University Urate oxidase
WO2000007629A2 (en) * 1998-08-06 2000-02-17 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3451996A (en) * 1968-02-12 1969-06-24 Thompson Farms Co Method for the preparation of heparin
US3616231A (en) * 1968-11-14 1971-10-26 Boehringer Mannheim Gmbh Process for the production of uricase
US3931399A (en) * 1970-12-22 1976-01-06 Behringwerke Aktiengesellschaft Process for isolating a fibrin-stabilizing factor
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4169764A (en) * 1975-08-13 1979-10-02 Ajinomoto Co., Inc. Process for production of urokinase
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4301153A (en) * 1977-03-21 1981-11-17 Riker Laboratories, Inc. Heparin preparation
US4425431A (en) * 1978-04-20 1984-01-10 Toyo Soda Manufacturing Co., Ltd. Production of an allose-containing polysaccharide
US4312979A (en) * 1978-04-20 1982-01-26 Toyo Soda Manufacturing Co., Ltd. Polysaccharides containing allose
JPS6031472B2 (en) * 1978-12-14 1985-07-22 協和醗酵工業株式会社 acid uricase
JPS5599189A (en) 1979-01-22 1980-07-28 Mihama Hisaharu Modified uricase free from antigenicity and its preparation
DE2916711A1 (en) * 1979-04-25 1980-11-06 Behringwerke Ag Blood coagulation factors and process for their manufacture
FR2475900A1 (en) * 1980-02-20 1981-08-21 Fabre Sa Pierre VACCINE COMPLEX CONTAINING A SPECIFIC ANTIGEN AND VACCINE CONTAINING SAME
JPS5740503A (en) * 1980-08-22 1982-03-06 Seikagaku Kogyo Co Ltd Separation of saccharides
FR2497006A1 (en) 1980-12-24 1982-06-25 Ind Electro Ste Gle ELECTRICAL CONTACTS FOR COAXIAL CABLES AND BIFILIC CABLES
DE3126759A1 (en) * 1981-07-07 1983-01-27 Boehringer Mannheim Gmbh, 6800 Mannheim SOLUBLE LIVER URICASE, METHOD FOR THE PRODUCTION AND USE THEREOF
US4485176A (en) * 1982-06-28 1984-11-27 E. I. Du Pont De Nemours & Company Turbidimetric method for measuring protein in urine and cerebrospinal fluid
EP0109688A3 (en) * 1982-11-23 1986-12-03 The Wellcome Foundation Limited Improved complexes, processes for obtaining them and formulations containing such complexes
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
JPH0671425B2 (en) * 1985-06-05 1994-09-14 サッポロビール株式会社 Uricase and method for producing the same
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
AU597924B2 (en) * 1985-12-11 1990-06-14 Natinco Nv Solubilization of protein aggregates
DD279486A1 (en) 1986-03-10 1990-06-06 Akad Wissenschaften Ddr PROCESS FOR ACTIVATING HYDROXYL GROUP-CONTAINING POLYMER COMPOUNDS
JPS6255079A (en) 1986-04-23 1987-03-10 Mihama Hisaharu Modified uricase
AU612133B2 (en) * 1987-02-20 1991-07-04 Natinco Nv Production of proteins in active forms
CA1305285C (en) * 1987-04-21 1992-07-14 Malcolm Roy Brandon Production of proteins in active forms
AU609824B2 (en) * 1987-06-15 1991-05-09 Southern Cross Biotech Pty Ltd. Production of proteins in active forms
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US4945086A (en) * 1988-05-03 1990-07-31 The Board Of Trustees Of The Leland Stanford Junior University Smooth muscle cell growth inhibitor
US5955336A (en) * 1988-08-17 1999-09-21 Toyo Boseki Kabushiki Kaisha DNA sequence for uricase and manufacturing process of uricase
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5010183A (en) * 1989-07-07 1991-04-23 Macfarlane Donald E Process for purifying DNA and RNA using cationic detergents
NZ234453A (en) 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
US5382518A (en) * 1989-07-13 1995-01-17 Sanofi Urate oxidase activity protein, recombinant gene coding therefor, expression vector, micro-organisms and transformed cells
US5286637A (en) * 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
CA2065744A1 (en) * 1989-08-23 1991-02-24 Zvi Fuks Wound healing preparations containing heparanase
JPH03148298A (en) 1989-11-01 1991-06-25 Sumitomo Pharmaceut Co Ltd Modified peptide and production thereof
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5653974A (en) * 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
CA2112674C (en) * 1991-07-02 2005-10-04 John S. Patton Method and device for delivering aerosolized medicaments
YU66892A (en) 1991-08-20 1995-10-24 Hoechst Ag. PHOSPHOINOSYTOLGLICAN - A PEPTID WITH ACTION AS INSULIN
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5321095A (en) * 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
AU6240494A (en) 1993-02-16 1994-09-14 Enzon, Inc. Ribosome inactivating protein compositions having reduced antigenicity
JP3875730B2 (en) 1993-02-22 2007-01-31 サノフィ・アベンティス株式会社 Preventive and therapeutic agent for autoimmune diseases
US6385312B1 (en) * 1993-02-22 2002-05-07 Murex Securities, Ltd. Automatic routing and information system for telephonic services
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
ES2155472T3 (en) 1993-04-09 2001-05-16 Bio Technology General Corp NEW POLYPEPTIDE WITH INHIBITING ACTIVITY OF FACTOR XA.
AU7113594A (en) * 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
JPH09504174A (en) 1993-10-29 1997-04-28 インサイト ファーマシューティカルズ，インク． Chimeric protein containing protease nexin 1 mutant
US5795776A (en) * 1994-03-22 1998-08-18 Bio-Technology General Corp. Expression plasmids regulated by an OSMB promoter
FI96317C (en) * 1994-05-31 1996-06-10 Exavena Oy Method for the preparation of finely divided and modified starches
DE4423131A1 (en) * 1994-07-01 1996-01-04 Bayer Ag New hIL-4 mutant proteins as antagonists or partial agonists of human interleukin 4
US5633227A (en) * 1994-09-12 1997-05-27 Miles, Inc. Secretory leukocyte protease inhibitor as an inhibitor of tryptase
CA2206852A1 (en) * 1994-12-07 1996-06-13 Novo Nordisk A/S Polypeptide with reduced allergenicity
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
IL116696A (en) * 1995-01-25 1999-08-17 Bio Technology General Corp Production of enzymatically active recombinant carboxypeptidase b
FR2733914B1 (en) * 1995-05-11 1997-08-01 Sanofi Sa STABLE LIQUID COMPOSITION CONTAINING URATE OXYDASE AND LYOPHILIZED COMPOSITION FOR ITS PREPARATION
JPH09154581A (en) 1995-12-05 1997-06-17 Asahi Chem Ind Co Ltd Substantially pure microorganism capable of producing uricase
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
ES2275300T3 (en) 1997-01-15 2007-06-01 Phoenix Pharmacologics, Inc. MODIFIED TUMOR NECROSIS FACTOR.
KR100369838B1 (en) 1997-02-26 2003-09-29 주식회사 엘지생명과학 Protease as protein derived from nonstructural protein 3 of hepatitis c virus and method for manufacturing the same
JPH1175876A (en) * 1997-07-04 1999-03-23 Ajinomoto Co Inc Production of new microbial transglutaminase
DK1084136T3 (en) * 1998-06-01 2005-01-03 Genentech Inc Separation of monomers by an antibody from its multimers using ion exchange chromatography
PT1588716E (en) * 1998-08-06 2011-05-25 Mountain View Pharmaceuticals Peg-urate oxidase conjugates and use thereof
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US6429860B1 (en) * 1999-06-15 2002-08-06 Visicomp, Inc. Method and system for run-time visualization of the function and operation of a computer program
NZ520461A (en) * 2000-02-14 2005-03-24 First Opinion Corp Automated diagnostic system and method
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US20040105839A1 (en) 2001-11-28 2004-06-03 Myung-Ok Park Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same
JP2008535500A (en) * 2005-04-11 2008-09-04 サビエント ファーマセウティカルズ インク． Mutant urate oxidase and use thereof
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
CN101622270B (en) * 2006-04-12 2014-01-01 萨文特医药公司 Method for purification of proteins with cationic surfactant

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000008196A2 (en) * 1998-08-06 2000-02-17 Duke University Urate oxidase
WO2000007629A2 (en) * 1998-08-06 2000-02-17 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE Geneseq [online] 19 June 2000 (2000-06-19), "N- and C-terminally truncated pig-baboon chimeric uricase (PBC-NT-CT).", XP002404208, retrieved from EBI accession no. GSP:AAY81255 Database accession no. AAY81255 *
DATABASE Geneseq [online] 30 May 2000 (2000-05-30), "Amino acid sequence of amino truncated chimeric pig-baboon uricase.", XP002404207, retrieved from EBI accession no. GSP:AAY69153 Database accession no. AAY69153 *
WU X ET AL: "URATE OXIDASE: PRIMARY STRUCTURE AND EVOLUTIONARY IMPLICATIONS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 86, December 1989 (1989-12-01), pages 9412 - 9416, XP002923290, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
IL223476A0 (en) 2013-02-03
MX2007012548A (en) 2008-03-11
US8034594B2 (en) 2011-10-11
SG10201706384VA (en) 2017-09-28
SG161248A1 (en) 2010-05-27
SG2014009484A (en) 2014-05-29
KR20080007360A (en) 2008-01-18
AU2006235437B2 (en) 2011-11-24
IL223477A (en) 2017-10-31
CN101194016A (en) 2008-06-04
US20110217755A1 (en) 2011-09-08
US8178334B2 (en) 2012-05-15
US20090209021A1 (en) 2009-08-20
US8465735B2 (en) 2013-06-18
US7964381B2 (en) 2011-06-21
IL186511A0 (en) 2008-01-20
US20120225046A1 (en) 2012-09-06
US20130084273A1 (en) 2013-04-04
RU2435847C2 (en) 2011-12-10
CZ2007700A3 (en) 2008-02-27
JP2013090636A (en) 2013-05-16
EP1871877A2 (en) 2008-01-02
PL215157B1 (en) 2013-10-31
IL208643A0 (en) 2011-07-31
EP2918676A1 (en) 2015-09-16
US8293228B2 (en) 2012-10-23
PL384263A1 (en) 2008-07-21
BRPI0612942A2 (en) 2012-10-09
HU229626B1 (en) 2014-03-28
JP2008535499A (en) 2008-09-04
US7811800B2 (en) 2010-10-12
EP2918676B1 (en) 2018-01-31
KR101304289B1 (en) 2013-09-12
IL281228A (en) 2021-04-29
HUP0700729A2 (en) 2008-03-28
IL256157A (en) 2018-02-28
CA2604545A1 (en) 2006-10-19
CN101194016B (en) 2012-09-05
US20110104751A1 (en) 2011-05-05
IL256157B (en) 2021-03-25
JP2015077144A (en) 2015-04-23
NZ562291A (en) 2010-02-26
IL186511A (en) 2012-12-31
IL223476A (en) 2017-12-31
CN102807973A (en) 2012-12-05
WO2006110761A2 (en) 2006-10-19
HUP0700729A3 (en) 2012-09-28
IL223477A0 (en) 2013-02-03
RU2007141683A (en) 2009-05-20
US20120070876A1 (en) 2012-03-22
TW200716751A (en) 2007-05-01
AU2006235437A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
WO2006110761A3 (en) A variant form of urate oxidase and use thereof
WO2006110819A3 (en) Variant forms of urate oxidase and use thereof
WO2007109221A3 (en) Methods for reducing protein aggregation
WO2006033859A3 (en) Compositions and methods for protein production
WO2006071613A3 (en) Injectable non-aqueous suspension
WO2006082254A3 (en) Microorganisms comprising enzymes expressed with low gamma-elimination activity
WO2005094235A3 (en) Toasted soybean flakes and method of making same
WO2006138418A3 (en) Improvement of cognitive performance with sirtuin activators
WO2006020767A3 (en) Thiazole based inhibitors of atp-utilizing enzymes
WO2006071693A3 (en) Injectable non-aqueous suspension
WO2006063055A3 (en) Enzyme conjugates for use as detoxifying agents
WO2008047150A3 (en) Protein variants
CA109169S (en) Sphygmomanometer
WO2006111524A3 (en) Il-21 variants
WO2005074655A3 (en) Materials and method for promotion of nerve regeneration
EP1829968A4 (en) Mutant protein having peptide-production activity
WO2006100679A3 (en) Recombinant antibodies against human type ii transglutaminase and uses thereof
WO2007051785A3 (en) Use of sdf-1 for the treatment and/or prevention of neurological diseases
WO2006001911A3 (en) Crystal structure of the hepatocyte growth factor beta chain and methods of use
EP1961816A4 (en) Novel highly functional enzyme having modified substrate-specificity
WO2007038264A3 (en) Gapr-1 methods
WO2006065126A3 (en) Terpene hydroxylation
WO2005077397A3 (en) Methods and compositions for treating vascular diseases
WO2007007060A3 (en) N- or c- terminally modified small peptides
WO2006085228A3 (en) 9a-carbamoyl-y-aminopropyl and 9a-thiocarbamoyl-y-aminopropyl-azalides with antimalarial activity

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680020689.8

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 11539475

Country of ref document: US

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2006235437

Country of ref document: AU

Ref document number: 2006740863

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 562291

Country of ref document: NZ

Ref document number: 3808/KOLNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2008505656

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 186511

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2604545

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/012548

Country of ref document: MX

Ref document number: PV2007-700

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 384263

Country of ref document: PL

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006235437

Country of ref document: AU

Date of ref document: 20060411

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P0700729

Country of ref document: HU

WWE Wipo information: entry into national phase

Ref document number: 1020077026114

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007141683

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 11918296

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0612942

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20071011

WWE Wipo information: entry into national phase

Ref document number: 223477

Country of ref document: IL

Ref document number: 223476

Country of ref document: IL